Cutaneous AEs Linked to Immune Checkpoint Inhibitor Therapy
Cutaneous immune-related adverse events seen in 25 percent of cancer patients initiating ICI therapy with median onset time of 113 days
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.